About: Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
Creator	Zhang, Sheng Ding, Min Li, Tian Fu, Wenyan Hu, Shi Lei, Changhai Qian, Kewen
topic	covid:a8e53c77bc72f467723a7d5b8020875c0e96f8aa#this
Source	BioRxiv; MedRxiv
abstract	2019-nCoV, which is a novel coronavirus emerged in Wuhan, China, at the end of 2019, has caused at least infected 11,844 as of Feb 1, 2020. However, there is no specific antiviral treatment or vaccine currently. Very recently report had suggested that novel CoV would use the same cell entry receptor, ACE2, as the SARS-CoV. In this report, we generated a novel recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. An ACE2 mutant with low catalytic activity was also used in the study. The fusion proteins were then characterized. Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties. Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.
has issue date	2020-02-02(xsd:dateTime)
bibo:doi	10.1101/2020.02.01.929976
has license	medrxiv
sha1sum (hex)	a8e53c77bc72f467723a7d5b8020875c0e96f8aa
schema:url	https://doi.org/10.1101/2020.02.01.929976
resource representing a document's title	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
schema:publication	bioRxiv
resource representing a document's body	covid:a8e53c77bc72f467723a7d5b8020875c0e96f8aa#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/a8e53c77bc72f467723a7d5b8020875c0e96f8aa
is schema:about of	named entity 'SARS-CoV' named entity 'mutant' named entity 'affinity' named entity 'connecting' named entity 'immunoglobulin' named entity 'potential' named entity '2019' named entity 'coronavirus' named entity 'recombinant' named entity 'RECOMBINANT' named entity 'APPLICATIONS' covid:arg/a8e53c77bc72f467723a7d5b8020875c0e96f8aa named entity 'RECEPTOR' named entity 'CONNECTING' named entity 'THESE' named entity 'CURRENTLY' named entity 'DOMAIN' named entity 'ACE2' named entity 'IMMUNOGLOBULIN IGG1' named entity 'REACTIVITY' named entity 'HUMAN IMMUNOGLOBULIN' named entity 'EXERTED' named entity 'HUMAN' named entity 'HIGH' named entity 'PROPERTIES' named entity 'PROPHYLAXIS' named entity 'CHINA' named entity 'REGION' named entity 'USE' named entity 'ACE2' named entity '2019 NOVEL CORONAVIRUS' named entity 'ANTIVIRAL TREATMENT' named entity 'RECOMBINANT PROTEIN' named entity 'CAUSED' named entity 'LOW' named entity 'EXHIBIT' named entity 'BINDING' named entity 'CROSS' named entity 'PROTEIN ' named entity 'GENERATED' named entity 'SPECIFIC' named entity 'USED' named entity 'IN VITRO' named entity 'FOR DIAGNOSIS' named entity 'AFFINITY' named entity '2019-NCOV' named entity 'AT THE END' named entity 'TREATMENT' named entity 'NOVEL' named entity 'VACCINE' named entity 'CHARACTERIZED' named entity 'SARS-COV' named entity 'EXTRACELLULAR DOMAIN' named entity 'REPORT' named entity 'ENTRY' named entity '2019' named entity 'INFECTED' named entity 'HAVE' named entity 'CATALYTIC ACTIVITY' named entity 'FEB' named entity 'MUTANT' named entity 'POTENTIAL' named entity 'PROTEINS' named entity 'FUSION' named entity 'CELL' named entity 'STUDY' named entity 'RECENTLY' named entity 'CORONAVIRUSES' named entity 'PHARMACOLOGICAL' named entity 'caused' named entity 'suggested' named entity 'study' named entity 'antiviral treatment' named entity 'ACE2' named entity 'fusion proteins' named entity 'catalytic activity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software